posted on 2025-10-07, 05:23authored byMiguel Isaiah Cruz
Triple negative breast cancer (TNBC) is an aggressive subset of breast cancer associated with poor prognosis, defined by the absence of three key receptors . While combined chemoimmunotherapy is the standard of care, there is a lack of effective targeted therapies. NRBP1 is an oncogene in breast cancer, but the mechanisms of how it drives cancer are unclear. My thesis integrates bioinformatics, recombinant protein assays and mass spectrometric techniques to understand how NRBP1 functions in TNBC. I identified key cellular signalling mechanisms regulated by NRBP1, highlighting NRBP1 as a potential target for therapeutic intervention.
History
Principal supervisor
Roger Daly
Additional supervisor 1
Joseph Rosenbluh
Additional supervisor 2
Ralf Schittenhelm
Year of Award
2025
Department, School or Centre
Biochemistry and Molecular Biology
Additional Institution or Organisation
Monash Biomedicine Discovery Institute
Campus location
Australia
Course
Doctor of Philosophy
Degree Type
DOCTORATE
Faculty
Faculty of Medicine, Nursing and Health Sciences
Rights Statement
The author retains copyright of this thesis. It must only be used for personal non-commercial research, education and study. It must not be used for any other purposes and may not be transmitted or shared with others without prior permission. For further terms use the In Copyright link under the License field.